中心静脉通路装置用于全身抗癌治疗(CAVA):一项随机对照试验
CAVA 开放标签多中心随机试验比较 Hickman 导管、PICC 与输液港在全身抗癌治疗中的并发症率。
要点
- 输液港并发症率显著低于 Hickman 导管和 PICC。
- PICC 与 Hickman 并发症率相近,但非劣性未获证实。
- 英国 NHS 中多数实体瘤 SACT 患者宜选用输液港。
核心结论
- 对多数接受 SACT 的患者,输液港比 Hickman 和 PICC 更有效且更安全。
- 研究提示英国 NHS 中多数实体瘤 SACT 患者应使用输液港。
研究设计与样本
- 开放标签、多中心、随机对照试验(CAVA),在英国 18 个肿瘤单位开展。
- 纳入 ≥18 岁、接受 ≥12 周 SACT 的实体瘤或血液恶性肿瘤成人。
- 随机分组采用最小化算法,按中心、BMI、癌症类型、装置史和治疗模式分层。
- 比较:PICC vs Hickman(非劣性,10% 界值);PORT vs Hickman(优效性,15% 界值);PORT vs PICC(优效性,15% 界值)。
- 主要结局为并发症率复合终点,随访至装置移除、退出研究或 1 年。
临床怎么用
- 对多数接受 SACT 的患者,尤其实体瘤患者,可优先考虑输液港以降低并发症风险。
- 选择 PICC 或 Hickman 时需权衡并发症风险,PICC 非劣于 Hickman 尚未证实。
局限性
- PICC 非劣性未获证实可能因把握度不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hickman-type tunnelled catheters (Hickman), peripherally inserted central catheters (PICCs), and totally implanted ports (PORTs) are used to deliver systemic anticancer treatment (SACT) via a central vein. We aimed to compare complication rates and costs of the three devices to establish acceptability, clinical effectiveness, and cost-effectiveness of the devices for patients receiving SACT. METHODS: We did an open-label, multicentre, randomised controlled trial (Cancer and Venous Access [CAVA]) of three central venous access devices: PICCs versus Hickman (non-inferiority; 10% margin); PORTs versus Hickman (superiority; 15% margin); and PORTs versus PICCs (superiority; 15% margin). Adults (aged ≥18 years) receiving SACT (≥12 weeks) for solid or haematological malignancy from 18 oncology units in the UK were included. Four randomisation options were available: Hickman versus PICCs versus PORTs (2:2:1), PICCs versus Hickman (1:1), PORTs versus Hickman (1:1), and PORTs versus PICCs (1:1). Randomisation was done using a minimisation algorithm stratifying by centre, body-mass index, type of cancer, device history, and treatment mode. The primary outcome was complication rate (composite of infection, venous thrombosis, pulmonary embolus, inability to aspirate blood, mechanical failure, and other) assessed until device removal, withdrawal from study, or 1-year follow-up. This study is registered with ISRCTN, ISRCTN44504648. FINDINGS: Between Nov 8, 2013, and Feb 28, 2018, of 2714 individuals screened for eligibility, 1061 were enrolled and randomly assigned, contributing to the relevant comparison or comparisons (PICC vs Hickman n=424, 212 [50%] on PICC and 212 [50%] on Hickman; PORT vs Hickman n=556, 253 [46%] on PORT and 303 [54%] on Hickman; and PORT vs PICC n=346, 147 [42%] on PORT and 199 [58%] on PICC). Similar complication rates were observed for PICCs (110 [52%] of 212) and Hickman (103 [49%] of 212). Although the observed difference was less than 10%, non-inferiority of PICCs was not confirmed (odds ratio [OR] 1·15 [95% CI 0·78-1·71]) potentially due to inadequate power. PORTs were superior to Hickman with a complication rate of 29% (73 of 253) versus 43% (131 of 303; OR 0·54 [95% CI 0·37-0·77]). PORTs were superior to PICCs with a complication rate of 32% (47 of 147) versus 47% (93 of 199; OR 0·52 [0·33-0·83]). INTERPRETATION: For most patients receiving SACT, PORTs are more effective and safer than both Hickman and PICCs. Our findings suggest that most patients receiving SACT for solid tumours should receive a PORT within the UK National Health Service. FUNDING: UK National Institute for Health Research Health Technology Assessment Programme.
引用
- Moss JG, Wu O, Bodenham AR, et al. Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial. Lancet. 2021. PMID: 34297997. doi:10.1016/S0140-6736(21)00766-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。